J&J’s RIPTAC prostate cancer debut lands with unusually deep PSA responses
Johnson & Johnson used ESMO to put its newly acquired RIPTAC platform in front of the prostate cancer field with a first look that arrived with real commercial and scientific stakes attached. The company paid more than $3 billion for Halda Therapeutics in November 2025, and this conference readout is the first public evidence that the deal may translate into a new therapeutic lane rather than a one-off acquisition story.
The lead molecule, HLD-0915, is designed as a regulated induced proximity targeting chimera: a bifunctional small molecule that binds a tumor-specific protein and a second protein essential for cell survival. In practical terms, the strategy aims to force cancer cells into self-destruction through a “hold and kill” mechanism, while also trying to sidestep the resistance pathways that eventually blunt many targeted therapies. In advanced prostate cancer, where tumors often adapt to androgen-axis pressure with remarkably efficient escape routes, that concept has immediate appeal.
J&J framed the data as proof of concept for a mechanism that could matter even when standard hormone-directed drugs stop working. The company’s oncology leadership went further than cautious corporate language usually allows.
“Best data we’ve ever seen” was the phrase used to describe the readout.
Deep androgen-pathway pressure, then a different kind of biology
The study population consisted of patients with metastatic castration-resistant prostate cancer, or mCRPC, a setting defined by continued progression despite treatments aimed at the androgen receptor pathway. J&J also pointed to the broader survival range typically seen in this disease, citing a median overall survival of around 13.5 to 31.6 months depending on metastatic site. Liver involvement and other visceral spread often carry the worst prognosis, and responses to older androgen-axis therapies can be limited once tumors become fully resistant.
Against that background, the clinical activity looked strikingly deep. In the company’s latest dataset, 75% of patients had now experienced a confirmed complete or partial response. In the subgroup of 38 patients treated at the 50 mg dose, 77% achieved a confirmed prostate-specific antigen reduction of at least 50%, and 48% reached a PSA decline of 90% or more. Those kinds of biomarker shifts are not trivial in mCRPC, where PSA often serves as an early barometer of whether the tumor is still under biologic control.
The earlier Halda readout had already hinted at the drug’s potential. Among 22 patients who completed at least two cycles of once-daily oral therapy across dose levels, 59% had a PSA reduction greater than 50%. The ESMO update extends that signal into a larger and more focused cohort, with the 50 mg dose emerging as the clearest benchmark so far.
A single oral agent producing this level of PSA suppression in a resistant metastatic setting is what gives the program its momentum. It suggests the mechanism may be hitting a tumor dependency that survives after androgen receptor blockade has lost its edge, rather than merely nudging the same biology from a slightly different angle.
Safety signals stayed mostly low-grade, with one discontinuation
The safety profile did not show the kind of widespread toxicity that can quickly narrow enthusiasm for a first-in-class mechanism. Nausea occurred in 19% of patients, fatigue in 16%, and elevated triglycerides in 13%. Every one of those events was grade 1 or 2. Only one grade 3 event was reported, and only one patient discontinued treatment because of a side effect.
That matters because J&J had expected androgen-related effects to surface more clearly. Androgen signaling touches several organs, so a compound built to interact with that axis could reasonably have been expected to generate a broader adverse-event burden. The apparent absence of a more obvious class effect raises an important mechanistic question: the balance between androgen and BRD4 engagement may be central not only to efficacy but also to tolerability.
In other words, the drug may be finding a therapeutic window that is wide enough to be clinically useful, at least in the early data. For a first-in-human platform in an advanced solid tumor, that is exactly the kind of combination developers want to see: substantial biologic activity without a dominant safety penalty.
Phase 2 is underway, and phase 3 is about to begin
J&J has already moved JNJ-6143 into a phase 2 study at the 50 mg daily dose in about 100 patients with metastatic androgen pathway modulation-resistant prostate cancer, a disease state in which the cancer has spread and no longer responds to hormone therapy. A phase 3 trial is set to begin next week. The company has also advanced another RIPTAC with the same underlying concept into the clinic earlier this year, and it says roughly 20 additional programs are moving through discovery for future tumor-specific development.
The commercial subtext is obvious. J&J is already one of the major incumbents in prostate cancer, with Zytiga and Erleada on the market. A successful RIPTAC could extend that position from androgen suppression into a more ambitious strategy: killing resistant cells directly while preserving the convenience of oral dosing.
The biggest unanswered issue remains survival. PSA responses, even very deep ones, do not guarantee that overall survival will track in the same direction, especially in a disease with heterogeneous metastatic behavior and multiple prior treatment exposures. The upcoming randomized studies will need to show whether the early biomarker momentum turns into durable control of liver, lymph node, and other measurable disease sites. For now, the most concrete signal is simple: a first-generation RIPTAC has produced unusually strong activity in a prostate cancer population that has already outlived the usefulness of standard hormonal pressure.